Open AccessEffects of Metformin and Rosiglitazone Monotherapy on Insulin-Mediated Hepatic Glucose Uptake and Their Relation to Visceral Fat in Type 2 Diabetes
Author(s) -
Patricia Iozzo,
Kirsti Hällsten,
Vesa Oikonen,
Kirsi A. Virtanen,
Riitta Parkkola,
Jukka Kemppainen,
Olof Solin,
Fredrik Lönnqvist,
Ele Ferrannini,
Juhani Knuuti,
Pirjo Nuutila
Publication year - 2003
Publication title -
diabetes care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.636
H-Index - 363
eISSN - 1935-5548
pISSN - 0149-5992
DOI - 10.2337/diacare.26.7.2069
Subject(s) - metformin , rosiglitazone , medicine , endocrinology , placebo , insulin , type 2 diabetes , diabetes mellitus , glucose uptake , thiazolidinedione , hyperinsulinemia , carbohydrate metabolism , insulin resistance , pathology , alternative medicine
Impaired insulin-mediated hepatic glucose uptake (HGU) has been implicated in the hyperglycemia of type 2 diabetes. We examined the effects of metformin (2 g/day) and rosiglitazone (8 mg/day) monotherapy on HGU and its relation to subcutaneous fat, visceral fat (VF), and whole-body insulin-mediated glucose metabolism in type 2 diabetic patients.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom